← Browse by Condition
Medical Condition
urothelial carcinoma
Total Trials
12
Recruiting Now
12
Trial Phases
Phase 2, Phase 1, Phase 2, Phase 3
ClinicalMetric tracks all active clinical trials for urothelial carcinoma sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.
Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.
Frequently Asked Questions — urothelial carcinoma Clinical Trials
How many clinical trials are currently recruiting for urothelial carcinoma?
ClinicalMetric currently tracks 12 actively recruiting clinical trials for urothelial carcinoma, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 12. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for urothelial carcinoma?
urothelial carcinoma research spans Phase 1 (2 trials), Phase 2 (6 trials), Phase 3 (2 trials). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a urothelial carcinoma clinical trial?
Eligibility criteria for urothelial carcinoma trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 1 2
Phase 2 6
Phase 3 2
Top Sponsors
1 trial
1 trial
1 trial
1 trial
1 trial
Recruiting Clinical Trials
NCT07789119
Recruiting
Enrollment
50,000 pts
Location
United States
Sponsor
M.D. Anderson Cancer Center
NCT07183319 Phase 2
Recruiting
Enrollment
30 pts
Location
United States
Sponsor
University of Oklahoma
NCT07421700 Phase 1, Phase 2
Recruiting
Enrollment
132 pts
Location
United States, Austr...
Sponsor
Pfizer
NCT07908979 Phase 2
Recruiting
Enrollment
70 pts
Location
United States
Sponsor
Fox Chase Cancer Center
NCT06356155 Phase 2
Recruiting
Enrollment
32 pts
Location
United States
Sponsor
University of Michigan Rogel C...
NCT05302284 Phase 3
Recruiting
Enrollment
452 pts
Location
China
Sponsor
RemeGen Co., Ltd.
NCT06405425 Phase 2
Recruiting
Enrollment
52 pts
Location
China
Sponsor
Sichuan Baili Pharmaceutical C...
NCT06592326 Phase 3
Recruiting
Enrollment
460 pts
Location
China
Sponsor
Mabwell (Shanghai) Bioscience ...
NCT05321316
Recruiting
Enrollment
20 pts
Location
China
Sponsor
Peking University Cancer Hospi...
NCT07169734 Phase 1, Phase 2
Recruiting
Enrollment
180 pts
Location
United States, Franc...
Sponsor
Alentis Therapeutics AG
NCT06101290
Recruiting
Enrollment
150 pts
Location
United States
Sponsor
University of California, Davi...
NCT04970472
Recruiting
Enrollment
1,000 pts
Location
France
Sponsor
University Hospital, Toulouse
Related Conditions
bladder cancer (2) urothelial cancer (1) advanced metastatic urothelial cancer (1) muscle invasive bladder carcinoma (1) muscle invasive bladder urothelial carcinoma (1) her2 expressing (1) cervical squamous cell carcinoma (1) squamous non small cell lung cancer (1) colorectal cancer (1) intrahepatic cholangiocarcinoma (1) prostate cancer (1) oligoprogressive (1)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: November 2026 · Data Methodology